News – GeneTether, Inc.

Latest news

GeneTether Therapeutics Inc. Announces Second Quarter 2023 Financial Results

Vancouver, British Columbia – August 25, 2023

GeneTether Therapeutics Inc. Announces First Quarter 2023 Financial Results and Provides Corporate Update

Vancouver, British Columbia – May 25, 2023

GeneTether Therapeutics Engages Gad Berdugo, Managing Partner of Explorium Capital LLC, as Advisor to Explore Strategic Alternatives for GeneTether Technology Platform

Vancouver, British Columbia – May 1st, 2023

GeneTether Therapeutics Inc. Announces Fiscal Year 2022 Financial Results and Reports on Corporate Highlights

Vancouver, British Columbia – April 27, 2023

GeneTether Therapeutics Inc. Update – From the Desk of the CEO

Vancouver, British Columbia – March 30, 2023

GeneTether Therapeutics Inc. Announces Commencement of Strategic Review Process

Vancouver, British Columbia – February 08, 2023

GeneTether Therapeutics Inc. Announces Third Quarter 2022 Financial Results and Reports on Corporate Highlights

Vancouver, British Columbia – November 25, 2022

GeneTether Therapeutics Inc. Update – From the Desk of the CEO

Vancouver, British Columbia – October 25, 2022

GeneTether Therapeutics Inc. Announces Second Quarter 2022 Financial Results and Reports on Corporate Highlights

Vancouver, British Columbia – August 24, 2022

GeneTether Therapeutics Announces Issuance of New US Composition of Matter Patent for its Innovative Platform Technology Focused on Gene Editing Efficiency

San Lorenzo, California and Vancouver, British Columbia – May 25, 2022

GeneTether Therapeutics Inc. Announces First Quarter 2022 Financial Results and Reports on Corporate Highlights

Vancouver, British Columbia – May 26, 2022

GeneTether Therapeutics Publishes Paper on Novel Recombination Products in the CFTR Gene

San Lorenzo, California – May 11, 2022

GeneTether Therapeutics Inc. Announces Fiscal Year 2021 Financial Results and Reports on Corporate Highlights

Vancouver, British Columbia – April 28, 2022

GeneTether Therapeutics Completes Initial Public Offering and Announces Listing on the Canadian Securities Exchange

Kelowna, British Columbia – March 29, 2022

GeneTether Therapeutics Inc. Files Final Prospectus for Initial Public Offering of Units

Vancouver, British Columbia – March 22, 2022

GeneTether Therapeutics Inc. Receives Notice of Allowance from USPTO

Vancouver, British Columbia – February 14, 2022

GeneTether Therapeutics Inc. Files Amended and Restated Preliminary Prospectus for Initial Public Offering of Units

Vancouver, British Columbia – February 2, 2022

GeneTether Therapeutics Inc. Files Preliminary Prospectus for Initial Public Offering of Units

Vancouver, British Columbia – November 8, 2021

GeneTether Announces Organizational Changes Designed to Support Continued Growth

Berkeley, CA, October 19, 2021

GeneTether Closes First and Second Financing Tranches

Berkeley, CA, March 23, 2021

GeneTether TNT™ Platform Granted Australian Patent

Berkeley, CA, February 18, 2021

GeneTether Announces Organizational Changes

Berkeley, CA, February 18, 2021

GeneTether Co-Founder, Geoffrey Sargent, Ph.D., Recognized as a UC Berkeley Extension 2020 Inspirational Instructor

Berkeley, CA, Nov. 1, 2020